Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Shanghai Henlius Biotech

Request full access

Shanghai Henlius Biotech is joint venture company that provides clinical-stage biopharmaceutical services

Huangpu, ChinaFounded 2009Biotech & Life Sciences

About Shanghai Henlius Biotech

Shanghai Henlius Biotech, Inc. (2696.HK) is a global biopharmaceutical company established in 2010, focusing on providing affordable and high-quality biologic medicines. It was co-founded by Dr. Scott Liu and Dr. Weidong Jiang, both of whom brought over two decades of experience in drug development, R&D, and manufacturing from leading international biopharmaceutical firms. The company operates as a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co Ltd.

Henlius has built an integrated biopharmaceutical platform that encompasses the entire product lifecycle, from research and development to manufacturing and commercialization. The firm's business model revolves around the development and sale of monoclonal antibody (mAb) drugs, with a primary focus on oncology and autoimmune diseases. Its revenue is generated from product sales and licensing agreements. A significant milestone was achieved in September 2019 when Henlius completed a US$410 million initial public offering on the Hong Kong Stock Exchange. The company has established a global R&D presence with centers in Shanghai, Taipei, and California, and operates manufacturing facilities in Shanghai that are certified by Chinese, EU, and US GMP standards.

The company's product portfolio includes several commercially launched biologics. HANLIKANG (rituximab) was the first biosimilar developed and approved in China. HANQUYOU (trastuzumab), marketed as HERCESSI™ in the U.S. and Zercepac® in Europe, is a biosimilar used for HER2-positive breast and gastric cancer and is approved in China, the EU, and the U.S. Other key products include HANDAYUAN (adalimumab) for autoimmune diseases, HANBEITAI (bevacizumab) for various cancers, and HANSIZHUANG (serplulimab), the world's first anti-PD-1 mAb for the first-line treatment of extensive-stage small cell lung cancer (SCLC). Henlius is actively advancing a diversified pipeline of approximately 50 molecules, including antibody-drug conjugates (ADCs) and bispecific antibodies, and is exploring immuno-oncology combination therapies centered around its proprietary anti-PD-1 mAb, HANSIZHUANG.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2019

Shanghai Henlius Biotech in the Huangpu ecosystem

Live from Dealroom

The Shanghai Henlius Biotech office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later4 investors entered at this stage

  • CICC
  • Loyal Valley Capital
  • The Cathay Funds
  • ShenZhen GTJA Investment Group
Team profiled 11 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$26M

67 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See Shanghai Henlius Biotech on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.